Recruiting A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer NCT07325136 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more Locations Karmanos Cancer Institute — Detroit, Michigan, United States Local Institution - 0026 — Buffalo, New York, United States Duke Cancer Institute — Durham, North Carolina, United States University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States View more locations Show fewer locations Loading locations... View Trial Details
Recruiting This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer. NCT07249879 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more Locations Cancer Hospital, Chinese Academy of Medical Sciences — Beijing, Beijing Municipality, China Beijing Gobroad Hospital — Beijing, Beijing Municipality, China View Trial Details
Active, Not Recruiting A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) NCT05060016 Conditions Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases, +8 more Locations University of Alabama at Birmingham — Birmingham, Alabama, United States University of Arkansas for Medical Sciences — Little Rock, Arkansas, United States Christiana Care Health Services — Newark, Delaware, United States Moffitt Cancer Center — Tampa, Florida, United States View all 80 locations View more locations Show fewer locations Loading locations... View Trial Details
